Table 4 Range of net costs and QALYs resulting from scenarios and one-way sensitivity analyses
From: Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
QALY or cost per person | ||
|---|---|---|
Item varied | Lower | Upper |
Base case (per person): | not applicable | not applicable |
QALY gain 0.013 | ||
Net cost -£317 (ie cost saving for enoxaparin) | ||
Event free time gained | 0.004 QALYs | 0.014 QALYs |
Quality of life associated with event | 0.012 QALYs | na |
Treatment duration | -£298 | -£320 |
Length of stay | ||
Difference in length of stay | £42 (ie £3,305/QALY) | -£158 |
Cost per length of stay | -£236 | na |
Revascularisations | ||
Difference in coronary artery bypass grafting rates | -£140 | -£495 |
Difference in angioplasty rates | -£242 | -£368 |
Cost of coronary artery bypass grafting | -£309 | -£323 |
Cost of angioplasty | -£311 | -£360 |
Unfractionated heparin costs | ||
Unfractionated heparin loading dose and saline flush | -£314 | -£318 |
Unfractionated heparin drawn-up in saline | -£313 | -£318 |
Pump-related | -£312 | -£318 |
Monitoring (activate partial thromboplastin time tests) | -£308 | -£318 |
Nursing time | -£314 | -£318 |
Enoxaparin costs | -£314 | -£326 |
Scenario 3: Treatment of cardiac events | ||
(not mean length of stay) | ||
Myocardial infarction rate and recurrence of angina | -£174 | -£184 |
Cost to treat acute myocardial infarction | -£181 | -£187 |
Cost to treat angina | -£181 | -£189 |